AstraZeneca/MedImmune Effort to Resurrect FluMist Gets PR Boost And Dollars From HHS
This article was originally published in The Pink Sheet Daily
Winning the race to provide the first doses on H1N1 pandemic vaccine will help repair image for the inhaled vaccine; recent praise for the product as conveying protection in multiple ways could help also.
You may also be interested in...
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.